603880 Jiangsu Nanfang Medical
- 4.06
- +0.13+3.31%
Jiangsu Nanfang Medical News
ST Nanwei (603880.SH) announced first-quarter results, net profit of 1.75 million yuan, a year-on-year decrease of 74.82%
ST Nanwei (603880.SH) disclosed its report for the first quarter of 2024. The company achieved revenue of 1.3 during the reporting period...
ST Nanwei (603880.SH) announced 2023 annual results with a net loss of 147 million yuan
According to the Zhitong Finance App, ST Nanwei (603880.SH) disclosed the 2023 annual report. The company achieved revenue of 600 million yuan in 2023, an increase of 10.03%; net profit loss to mother was 147 million yuan, an increase over the previous year; loss after deducting non-net profit of 147 million yuan, a year-on-year increase; and basic earnings per share were -0.51 yuan. During the reporting period, the company's main business revenue increased slightly compared to last year; the decrease in net profit attributable to the parent company was mainly due to an oversupply of protective equipment, and price competition was intense; credit impairment losses and asset impairment losses increased.
ST Nanwei (603880.SH): There is no business involved in the AI medical field yet
Gelonghui, March 19丨ST Nanwei (603880.SH) said on the investor interactive platform that the company has no business involved in the AI medical field yet.
ST Nanwei (603880.SH): Shareholder Xu Dong has purchased 1.5565 million shares of the company
Gelonghui, Feb. 20 | ST Nanwei (603880.SH) announced that today the company received a notice from Mr. Xu Dong, a shareholder of more than 5%: As of February 20, 2024, Mr. Xu Dong had purchased 1,056,500 shares of the company through self-funded centralized bidding transactions in the secondary market. All proceeds from this share repurchase are owned by the listed company.
Jiangsu Nanfang Medical Co., Ltd. (SHSE:603880) Looks Inexpensive After Falling 28% But Perhaps Not Attractive Enough
The Jiangsu Nanfang Medical Co., Ltd. (SHSE:603880) share price has fared very poorly over the last month, falling by a substantial 28%. The drop over the last 30 days has capped off a tough year f
ST Nanwei (603880.SH): Jiangsu Securities Regulatory Bureau takes corrective regulatory measures against shareholder Xu Dong
ST Nanwei (603880.SH) issued an announcement. Recently, Xu Dong, a shareholder of more than 5% of the company, received the Jiangsu Securities Regulatory Bureau...
ST Nanwei (603880.SH) shareholder Xu Dong reduced the company's holdings by a total of 1,056,500 shares, and terminated the reduction in holdings early
ST Nanwei (603880.SH) issued an announcement. On December 15, 2023, the company received shareholder Xu Dong's “...
ST Nanwei (603880.SH) released the first three quarter results, net profit of 7.2626 million yuan, up 17.87% year on year
ST Nanwei (603880.SH) released its report for the first three quarters of 2023, with revenue of 470 million yuan, compared to the same period last year...
ST Nanwei (603880.SH) released first-half results, net profit of 7.904 million yuan, an increase of 26.67% over the previous year
ST Nanwei (603880.SH) released the 2023 semi-annual report. The company's revenue was 353 million yuan,...
ST Nanwei (603880.SH) director Xiang Qinhua reduced his holdings of the company by a total of 54,000 shares
ST Nanwei (603880.SH) issued an announcement. As of the announcement date, director Xiang Qinhua had reduced...
Li Ping, the controlling shareholder of ST Nanwei (603880.SH), plans to transfer 8% of the company's shares to Ren Weiguo to cash out 99.92 million yuan
According to the Zhitong Finance App, ST Nanwei (603880.SH) announced that Li Ping, the controlling shareholder of the company, plans to transfer the company's 23.4 million shares (about 8% of the company's total share capital) of unrestricted tradable shares to Ren Weiguo. The transfer price is 4.27 yuan/share, and the total transfer price (tax included) totals RMB 999.18 million. After the transfer of this agreement was completed, Li Ping's shareholding ratio of the company decreased from 40.63% to 32.63%, and Ren Weiguo's shareholding ratio reached 8%.
ST Nanwei (603880.SH): Xu Dong plans to reduce his shares by no more than 6%
On July 18丨ST Nanwei (603880.SH) announced that within 6 months after 15 trading days from the date of disclosure of this announcement, Mr. Xu Dong plans to reduce the number of shares held by no more than 5,849,480 shares through centralized bidding, that is, no more than 2% of the company's total shares. Within 6 months after 3 trading days from the date of disclosure of this announcement, Mr. Xu Dong plans to reduce the number of shares held by no more than 11,698,960 shares through bulk transactions, that is, no more than 4% of the company's total shares.
Xu Dong, the main shareholder of ST Nanwei (603880.SH), reduced his holdings by 1,8559 million shares
According to the Zhitong Finance App, ST Nanwei (603880.SH) announced that Xu Dong, a shareholder holding more than 5% of the company's shares, has reduced his holdings by 1,8559 million shares through centralized bidding transactions, accounting for 0.63% of the company's total share capital. The implementation period of the holdings reduction plan has ended, and the implementation of the holdings reduction plan has been completed.
CEO Ping Li, Jiangsu Nanfang Medical Co., Ltd.'s (SHSE:603880) Largest Shareholder Sees Value of Holdings Go Down 23% After Recent Drop
Key Insights Jiangsu Nanfang Medical's significant insider ownership suggests inherent interests in company's expansion 52% of the business is held by the top 4 shareholders Ownership research, co
Jiangsu Nanfang Medical Unit to Apply For 100 Million Yuan Bank Loan
06:04 AM EST, 03/03/2023 (MT Newswires) -- Jiangsu Nanfang Medical (SHA:603880) subsidiary Nanfang Eisai Pharmaceutical plans to apply for a 100 million yuan bank loan, according to a filing on Friday
The 21% Return This Week Takes Jiangsu Nanfang Medical's (SHSE:603880) Shareholders Three-year Gains to 35%
One simple way to benefit from the stock market is to buy an index fund. But if you choose individual stocks with prowess, you can make superior returns. Just take a look at Jiangsu Nanfang Medical
There Are Some Reasons To Suggest That Jiangsu Nanfang Medical's (SHSE:603880) Earnings A Poor Reflection Of Profitability
Shareholders were pleased with the recent earnings report from Jiangsu Nanfang Medical Co., Ltd. (SHSE:603880). Investors should be cautious however, as there some causes of concern deeper in the num
Nanwei shares: the cumulative reduction of 1.952 million shares by Xu Dong, a shareholder, accounts for 0.66% of the company's total equity.
Nanwei shares (603880) announced that during the period from October 11, 2021 to April 11, 2022, Xu Dong, the company's shareholder, reduced the number of shares in the company by means of centralized bidding and bulk trading, accounting for 0.66% of the company's total share capital. The deadline for the implementation of the reduction plan has ended, and the implementation of the reduction plan has been completed.
The latest announcement of Nanwei shares: Lanying Venture Capital, which holds 5.86% of the shares, intends to reduce its holdings in the form of clearance.
Nanwei Co., Ltd. announced that Lan Yingchuang, a shareholder with a stake of 5.86%, intends to reduce its stake by no more than 5.86%. The chairman of the company is Li Ping. Mr. Li Ping: born in June 1961, Chinese nationality, no right of abode abroad, college degree, senior economist, senior operator, manager of Wujin Huanghu seed Farm Industrial Company from December 1984 to August 1993, joined the company in September 1994, served as factory director, chairman and general manager, and has been the supervisor of Changzhou Yangping Machinery Manufacturing Co., Ltd since March 2009. Chairman of Jiangsu Zuo Biopharmaceutical Co., Ltd., since August 2015, 2
Li Ping, chairman of Nanwei Co., Ltd. (603880.SH), acts as secretary to the board of directors.
Zhitong Financial App News, Nanwei shares (603880.SH) announced that the third session of the board of directors of the company is about to expire, and Ms. Li Fei, secretary of the third session of the board of directors, will no longer be re-appointed as secretary to the board of directors due to work adjustment. Mr. Li Ping, chairman of the company, will temporarily act as secretary to the board of directors before appointing a new secretary to the board of directors.
Analysis
Price Target
No Data
